{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:16:32Z","timestamp":1790687792655,"version":"4.1.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>While HIV-1 subtype C (HIV-1C) is the most prevalent and widely distributed subtype in the HIV pandemic, nearly all current prevention and therapeutic strategies are based on work with the subtype B (HIV-1B). HIV-1C displays distinct genetic and pathogenic features from that of HIV-1B. Thus, treatment approaches developed for HIV-1B need to be suitably optimized for HIV-1C. A suitable animal model will help delineate  comparative aspects of HIV-1C and HIV-1B infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, we used a humanized mouse model to evaluate HIV-1C infection, disease progression, response to anti-retroviral therapy (ART) and viral rebound following therapy interruption. A limited comparative study with a prototypical subtype B virus was also performed. Viral infection, immune cell dynamics, acquisition of anti-retroviral therapy (ART) resistance and anatomical reservoir distribution following extended and interrupted therapy were compared. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In comparison, lower early plasma viremia was observed with HIV-1C, but with similar rate of CD4+ T cell depletion as that of HIV-1B. Viral suppression by ART was delayed in the HIV-1C infected group with evidence, in one case, of acquired class wide resistance to integrase inhibitors, a critical component of current global therapy regimens. Also, HIV-1C infected animals displayed faster rebound viremia following ART interruption (ATI). Disparate patterns of tissue proviral DNA distribution were observed following extended ART and ATI suggestive of distinct sources of viral rebound. <\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In this preliminary study, discernible differences were noted between HIV-1C and B with implications for prevention, therapeutics and curative strategies. Results from here also highlight the utility of the hu-HSC mouse model for future expanded studies in this context.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1552563","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:10:54Z","timestamp":1744776654000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing HIV-1 subtype C infection dynamics, therapeutic responses and reservoir distribution using a humanized mouse model"],"prefix":"10.3389","volume":"16","author":[{"given":"Snehal","family":"Kaginkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Remling-Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashashree","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswini","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranay","family":"Gurav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Sutar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivasankar","family":"Panickan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Akkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vainav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00151-4","article-title":"Global and regional genetic diversity of HIV-1 in 2010\u201321: systematic review and analysis of prevalence","volume":"5","author":"Nair","year":"2024","journal-title":"Lancet Microbe"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02051-08","article-title":"CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic","volume":"83","author":"Abraha","year":"2009","journal-title":"J Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00253-17","article-title":"Subtype-specific differences in gag-protease-driven replication capacity are consistent with intersubtype differences in HIV-1 disease progression","volume":"91","author":"Kiguoya","year":"2017","journal-title":"J Virol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01832-18","article-title":"HIV subtype and nef-mediated immune evasion function correlate with viral reservoir size in early-treated individuals","volume":"93","author":"Omondi","year":"2019","journal-title":"J Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01376-22","article-title":"Enhanced transcriptional strength of HIV-1 subtype C minimizes gene expression noise and confers stability to the viral latent state","volume":"97","author":"Pal","year":"2023","journal-title":"J Virol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1997.8980","article-title":"Differences in chemokine coreceptor usage between genetic subtypes of HIV-1","volume":"241","author":"Tscherning","year":"1998","journal-title":"Virology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/v11121104","article-title":"HIV-1 latency and latency reversal: Does subtype matter","volume":"11","author":"Sarabia","year":"2019","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1393.1393","article-title":"Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse","volume":"84","author":"Akkina","year":"1994","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.virol.2012.10.007","article-title":"New generation humanized mice for virus research: Comparative aspects and future prospects","volume":"435","author":"Akkina","year":"2013","journal-title":"Virology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2012.03.009","article-title":"Humanized mice: Current states and perspectives","volume":"146","author":"Garcia","year":"2012","journal-title":"Immunol Lett"},{"key":"B11","unstructured":"Disseminated and sustained HIV infection in CD34 cord blood cell-transplanted Rag2\/c\/mice\n          \n          \n            \n              Baenziger\n              S\n            \n            \n              Tussiwand\n              R\n            \n            \n              Schlaepfer\n              E\n            \n            \n              Mazzucchelli\n              L\n            \n            \n              Heikenwalder\n              M\n            \n            \n              Kurrer\n              MO\n            \n          \n          \n          2006"},{"key":"B12","article-title":"Humanized mouse models of HIV infection","volume":"13","author":"Denton","year":"2011","journal-title":"AIDS Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01889","article-title":"Cross-species transmission and evolution of SIV chimpanzee progenitor viruses toward HIV-1 in humanized mice","volume":"11","author":"Schmitt","year":"2020","journal-title":"Front Microbiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015257","article-title":"Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model","volume":"5","author":"Neff","year":"2010","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-016-2942-4","article-title":"VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice","volume":"161","author":"Sun","year":"2016","journal-title":"Arch Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00746","article-title":"The use of the humanized mouse model in gene therapy and immunotherapy for HIV and cancer","volume":"9","author":"Carrillo","year":"2018","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217887120","article-title":"CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice","volume":"120","author":"Dash","year":"2023","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2016.11.013","article-title":"A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy","volume":"501","author":"Hu","year":"2017","journal-title":"Virology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/jmp.2018.47.issue-5","article-title":"SIV progenitor evolution toward HIV: A humanized mouse surrogate model for SIVsm adaptation toward HIV-2","volume":"47","author":"Schmitt","year":"2018","journal-title":"J Med Primatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn5866","article-title":"Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates","volume":"385","author":"Pitchai","year":"2024","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jviromet.2016.03.008","article-title":"Comparison of three quantification methods for the TZM-bl pseudovirus assay for screening of anti-HIV-1 agents","volume":"233","author":"Xing","year":"2016","journal-title":"J Virol Methods"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jmp.12674","article-title":"Characterizing the phenotypic and genetic changes of pre-epidemic HIV-2 group F virus following serial passage in humanized mice","volume":"52","author":"Curlin","year":"2023","journal-title":"J Med Primatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jmp.12486","article-title":"Evolution of SIVsm in humanized mice towards HIV-2","volume":"49","author":"Curlin","year":"2020","journal-title":"J Med Primatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-018-1101-9","article-title":"Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART","volume":"15","author":"Rochat","year":"2018","journal-title":"Virol J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.634647","article-title":"Vaginal epithelium transiently harbours HIV-1 facilitating transmission","volume":"11","author":"Prabhu","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2019.113737","article-title":"Single genome sequencing of near full-length HIV-1 RNA using a limiting dilution approach","volume":"274","author":"Hebberecht","year":"2019","journal-title":"J Virol Methods"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02010-06","article-title":"Human immunodeficiency virus type 1 pathobiology studied in humanized BALB\/c-rag2 \u2013\/\u2013 \u03b3 c \u2013\/\u2013 mice","volume":"81","author":"Gorantla","year":"2007","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.10.014","article-title":"Infecting HIV-1 subtype predicts disease progression in women of Sub-Saharan Africa","volume":"13","author":"Venner","year":"2016","journal-title":"EBioMedicine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-85","article-title":"Subtype-associated differences in HIV-1 reverse transcription affect the viral replication","volume":"7","author":"Iordanskiy","year":"2010","journal-title":"Retrovirology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00253-17","article-title":"Subtype-specific differences in gag-protease-driven replication capacity are consistent with intersubtype differences in HIV-1 disease progression","volume":"91","author":"Kiguoya","year":"2017","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-13-4","article-title":"Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy","volume":"13","author":"Easterbrook","year":"2010","journal-title":"J Int AIDS Soc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00182","article-title":"Delineation of homeostatic immune signatures defining viremic non-progression in HIV-1 infection","volume":"11","author":"Singh","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100537","DOI":"10.1016\/j.medj.2024.10.014","article-title":"HIV viremic non-progressors: More clues and more questions","volume":"6","author":"Hitschfel","year":"2025","journal-title":"Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4314\/ejhs.v29i6.12","article-title":"Predictors of time to viral load suppression of adult PLWHIV on ART in Arba Minch General Hospital: A follow up study","volume":"29","author":"Hussen","year":"2019","journal-title":"Ethiop J Health Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1086\/598502","article-title":"Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy","volume":"48","author":"Geretti","year":"2009","journal-title":"Clin Infect Diseases"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107049","article-title":"Rapid ART initiation with bictegravir\/emtricitabine\/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study)","volume":"63","author":"Camici","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"B38","unstructured":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture\n          \n          \n            \n              Brenner\n              BG\n            \n            \n              Oliveira\n              M\n            \n            \n              Doualla-Bell\n              F\n            \n            \n              Moisi\n              DD\n            \n            \n              Ntemgwa\n              M\n            \n            \n              Frankel\n              F"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046622","article-title":"Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C","volume":"7","author":"Cunha","year":"2012","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1525646","article-title":"Primary HIV drug resistance among recently infected cases of HIV in north-west India","volume":"2019","author":"Chauhan","year":"2019","journal-title":"AIDS Res Treat"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab297","article-title":"Case report: emergent resistance in a treatment-naive person with human immunodeficiency virus under Bictegravir-based therapy","volume":"8","author":"Chamberlain","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.v24.11","article-title":"Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series","volume":"24","author":"DeKoven","year":"2023","journal-title":"HIV Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f366ff","article-title":"Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance","volume":"22","author":"Gardner","year":"2009","journal-title":"AIDS"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu119","article-title":"Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia","volume":"2","author":"Konstantopoulos","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa346","article-title":"ART adherence, resistance, and long-term HIV viral suppression in postpartum women","volume":"7","author":"Redd","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.v95.10","article-title":"Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study","volume":"95","author":"Oomen","year":"2023","journal-title":"J Med Virol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000953","article-title":"The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption","volume":"30","author":"Li","year":"2016","journal-title":"AIDS"},{"key":"B49","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.medj.2022.06.009","article-title":"Acute HIV-1 infection viremia associate with rebound upon treatment interruption","volume":"3","author":"Mdluli","year":"2022","journal-title":"Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2023.100320","article-title":"Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection","volume":"9","author":"Yuan","year":"2023","journal-title":"J Virus Eradication"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.397158","article-title":"Multiple NF-\u03baB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance","volume":"287","author":"Bachu","year":"2012","journal-title":"J Biol Chem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00308-16","article-title":"Functional incompatibility between the generic NF-\u03baB motif and a subtype-specific sp1III element drives the formation of the HIV-1 subtype C viral promoter","volume":"90","author":"Verma","year":"2016","journal-title":"J Virol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0028","article-title":"HIV tissue reservoirs: current advances in research","volume":"37","author":"Li","year":"2023","journal-title":"AIDS Patient Care STDS"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162604","article-title":"Subtype C HIV-1 reservoirs throughout the body in ART-suppressed individuals","volume":"7","author":"Liu","year":"2022","journal-title":"JCI Insight"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152526","article-title":"Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART","volume":"6","author":"Obregon-Perko","year":"2021","journal-title":"JCI Insight"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201325","article-title":"Brain is a potential sanctuary for subtype C HIV-1 irrespective of ART treatment outcome","volume":"13","author":"Tso","year":"2018","journal-title":"PloS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s13365-015-0328-0","article-title":"Genetic diversity and proviral DNA load in different neural compartments of HIV-1 subtype C infection","volume":"21","author":"Mishra","year":"2015","journal-title":"J Neurovirol"},{"key":"B58","unstructured":"Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa\n          \n          \n            \n              Redd\n              AD\n            \n            \n              Avalos\n              A\n            \n            \n              Essex\n              M\n            \n          \n          \n          2007"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02053-23","article-title":"Identifying physiological tissue niches that support the HIV reservoir in T cells","volume":"14","author":"Ikeogu","year":"2023","journal-title":"mBio"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1051\/medsci\/200824121055","article-title":"Mesenteric lymph nodes, a sanctuary for the persistance of HIV","volume":"24","author":"Estaquier","year":"2008","journal-title":"Medecine\/Sciences"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/v11020105","article-title":"Persistent viral reservoirs in lymphoid tissues in SIV-infected rhesus macaques of Chinese-origin on suppressive antiretroviral therapy","volume":"11","author":"Siddiqui","year":"2019","journal-title":"Viruses"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S449615","article-title":"Detection of HIV-1 DNA\/RNA in peripheral blood, bone marrow and femoral head of patients with osteonecrosis of the femoral head","volume":"17","author":"Li","year":"2024","journal-title":"Infect Drug Resist"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir884","article-title":"HIV-1 DNA is detected in bone marrow populations containing CD4 + T cells but is not found in purified CD34 + hematopoietic progenitor cells in most patients on antiretroviral therapy","volume":"205","author":"Durand","year":"2012","journal-title":"J Infect Diseases"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cells11192968","article-title":"HIV-1 infection of long-lived hematopoietic precursors in vitro and in vivo","volume":"11","author":"Renelt","year":"2022","journal-title":"Cells"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02118-17","article-title":"HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational antiretroviral therapy","volume":"92","author":"Satheesan","year":"2018","journal-title":"J Virol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/laban.1279","article-title":"Tackling HIV and AIDS: Contributions by non-human primate models","volume":"6","author":"Van Rompay","year":"2017","journal-title":"Lab Animal"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215393110","article-title":"DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge","volume":"110","author":"Patel","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s13337-020-00595-x","article-title":"Analysis of sequence diversity and selection pressure in HIV-1 clade C gp41 from India","volume":"31","author":"Sutar","year":"2020","journal-title":"Virusdisease"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-021-00556-2","article-title":"Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities","volume":"18","author":"Mullick","year":"2021","journal-title":"Retrovirology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198370","article-title":"Intra-Clade C signature polymorphisms in HIV-1 LTR region: The Indian and African lookout","volume":"297","author":"Singh","year":"2021","journal-title":"Virus Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1552563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:10:57Z","timestamp":1744776657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1552563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2025.1552563"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1552563","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1552563"}}